Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.
Bendtsen SK, Perez-Penco M, Hübbe ML, Martinenaite E, Orebo Holmström M, Weis-Banke SE, Grønne Dahlager Jørgensen N, Jørgensen MA, Munir Ahmad S, Jensen KM, Friese C, Lundsager MT, Johansen AZ, Carretta M, Ødum N, Met Ö, Svane IM, Madsen DH, Andersen MH.
Bendtsen SK, et al.
Oncoimmunology. 2022 Jan 27;11(1):2026020. doi: 10.1080/2162402X.2022.2026020. eCollection 2022.
Oncoimmunology. 2022.
PMID: 35111385
Free PMC article.